Supplementation with vitamin B12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease.

Dierkes, J; Domröse, U; Ambrosch, A; Schneede, J; Guttormsen, A B; Neumann, K H; Luley, C

Dierkes, J; Domröse, U; Ambrosch, A; Schneede, J; Guttormsen, A B; Neumann, K H; Luley, C.

Affiliation

Dierkes J; Institute of Clinical Chemistry and Nephrology Clinic, University Hospital Magdeburg, Germany.

Metabolism ; 48(5): 631-5, 1999 May.

Article in En | MEDLINE | ID: mdl-10337865

Subject(s)

Folic Acid Antagonists/therapeutic use; Folic Acid/blood; Homocysteine/blood; Kidney Failure, Chronic/blood; Kidney Failure, Chronic/drug therapy; Methylmalonic Acid/blood; Vitamin B 12/therapeutic use; Adult; Aged; Dietary Supplements; Female; Folic Acid Antagonists/administration & dosage; Genotype; Homocysteine/antagonists & inhibitors; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Methylmalonic Acid/antagonists & inhibitors; Middle Aged; Oxidoreductases Acting on CH-NH Group Donors/genetics; Vitamin B 12/administration & dosage; Vitamin B 12/blood

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Vitamin B 12 / Folic Acid / Folic Acid Antagonists / Homocysteine / Kidney Failure, Chronic / Methylmalonic Acid Language: En Journal: Metabolism Year: 1999 Type: Article Affiliation country: Germany

Search on Google

Add to My VHL

XML

PubMed Links